Elucidating brain transport pathways and cell type-dependent gene silencing of a durable lipid–siRNA conjugate administered into cerebrospinal fluid

The clinical neurosciences are in the midst of a renaissance spurred by the development of new therapeutic modalities. Short interfering RNAs (siRNAs), in particular, are gaining interest for treating neurological diseases owing to their capacity to sustain inhibition of nearly any gene target. However, to be effective, siRNA therapies must achieve delivery and on-target gene silencing activity in specific sites and cells in the brain. To this end, we developed a lipid-siRNA conjugate (L2-siRNA) that transports effectively throughout the brain when injected into cerebrospinal fluid (CSF). We provide a detailed examination of regional bulk tissue gene silencing in mice, highlighting potent knockdown 5 months after a single injection without detectable toxicity. Intrathecal delivery of L2-siRNA in rats further illustrates effective transport and knockdown using a clinically relevant route of administration. Single-cell RNA sequencing was additionally performed in mice to generate an atlas of cell type-specific knockdown. Lastly, we benchmarked L2-siRNA gene silencing activity in different brain regions against antisense oligonucleotides, a related but different gene silencing modality. Collectively, this work examines properties of lipid-siRNA conjugates that facilitate CSF to brain delivery and supports L2-siRNA as a promising platform for silencing genes implicated in central nervous system disorders.

Authors

Institutions

Publication Details

Journal
Nucleic Acids Research
Published
2025-06-20
DOI
https://doi.org/10.1093/nar/gkaf600
Citations
5
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
4.03

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Elucidating brain transport pathways and cell type-dependent gene silencing of a durable lipid–siRNA conjugate administered into cerebrospinal fluid

Ketaki A. Katdare, Ella N. Hoogenboezem, Sarah M. Lyons, Timothy M. Miller et al.
5 citations
Nucleic Acids Research
RNA Interference and Gene Delivery
4.03
article

Elucidating brain transport pathways and cell type-dependent gene silencing of a durable lipid–siRNA conjugate administered into cerebrospinal fluid

Ketaki A. Katdare, Ella N. Hoogenboezem, Sarah M. Lyons, Timothy M. Miller, Joshua Park, Kasey C. Vickers, Lissa Ventura‐Antunes, Eva Fritsch, Mark Castleberry, Ethan S. Lippmann, Alexander P Ligocki, Alex Prusky, Alena Shostak, Craig L. Duvall, Nora Francini, Andrew Kjar, Kathleen M. Schoch, Matthew Schrag, Alexander G. Sorets, Danielle L. Michell, Katrina R Schwensen, W. T. Ford, Adam M Abdulrahman, Rebecca P. Cowell
article en
5 citations

Abstract

The clinical neurosciences are in the midst of a renaissance spurred by the development of new therapeutic modalities. Short interfering RNAs (siRNAs), in particular, are gaining interest for treating neurological diseases owing to their capacity to sustain inhibition of nearly any gene target. However, to be effective, siRNA therapies must achieve delivery and on-target gene silencing activity in specific sites and cells in the brain. To this end, we developed a lipid-siRNA conjugate (L2-siRNA) that transports effectively throughout the brain when injected into cerebrospinal fluid (CSF). We provide a detailed examination of regional bulk tissue gene silencing in mice, highlighting potent knockdown 5 months after a single injection without detectable toxicity. Intrathecal delivery of L2-siRNA in rats further illustrates effective transport and knockdown using a clinically relevant route of administration. Single-cell RNA sequencing was additionally performed in mice to generate an atlas of cell type-specific knockdown. Lastly, we benchmarked L2-siRNA gene silencing activity in different brain regions against antisense oligonucleotides, a related but different gene silencing modality. Collectively, this work examines properties of lipid-siRNA conjugates that facilitate CSF to brain delivery and supports L2-siRNA as a promising platform for silencing genes implicated in central nervous system disorders.

Nucleic Acids ResearchVol. 53(12)
Vanderbilt University (US), Washington University in St. Louis (US), Vanderbilt Health (US), Vanderbilt University Medical Center (US)
National Institutes of Health
Responsible consumption and production
Openalex Percentile: Top 6%
RNA Interference and Gene Delivery
4.03
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.